Posted by Michael Wonder on 27 May 2023
Iovance Biotherapeutics announces US FDA acceptance of the biologics license application of lifileucel for the treatment of advanced melanoma
26 May 2023 - Priority review granted with PDUFA action date of 25 November 2023.
Iovance Biotherapeutics today announced that the US FDA accepted its biologics license application for lifileucel for patients with advanced melanoma.
